

Drug Monograph

Drug Name: **Injectafer® (ferric carboxymaltose) 1000 mg/20 mL vial**
 Drug Class: **Hematologic Agents: Iron Supplement**
 Prepared For: MO HealthNet
 Prepared By: Conduent

☒ **New Criteria**

☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.	
Dosage Forms:	Injectafer is available in a 1,000 mg/20 mL vial.	
Manufacturer:	Distributed by: American Regent, Inc., Shirley, NY 11967.	
Indications:	Injectafer is indicated for the treatment of iron deficiency anemia (IDA) in: <ul style="list-style-type: none"> Adults and pediatric patients 1 year of age and older who have either intolerance to oral iron or an unsatisfactory response to oral iron Adult patients who have non-dialysis dependent chronic kidney disease.	
Costs:	Not Available	
Summary of Findings:	The MO Healthnet Division recommends adding this drug to the current Iron-Injectable Step Therapy clinical edit.	
Status	<input checked="" type="checkbox"/> Clinical Edit	<input type="checkbox"/> PA Required
Recommendation:	<input type="checkbox"/> Open Access	<input type="checkbox"/> PDL
Type of PA Criteria:	<input checked="" type="checkbox"/> Appropriate Indications	<input type="checkbox"/> Non-Preferred
	<input type="checkbox"/> No PA Required	<input type="checkbox"/> Preferred

Prepared by: April Ash, PharmD
 Date: December 30, 2021